article thumbnail

Osivax publishes phase 2a results supporting dual flu vaccine approach

Pharma Times

The results, now published in Vaccines , show that the combination was well-tolerated with no serious adverse events, and generated strong immune responses. Robust NP-specific humoral and cell-mediated immune responses were observed in all participants given OVX836, whether alone or with Fluarix Tetra.

article thumbnail

Alzheimer’s vaccine granted Fast Track designation

European Pharmaceutical Review

AC Immune SA has received Fast Track designation from the US Food and Drug Administration (FDA) for its anti-amyloid beta (Abeta) active immunotherapy vaccine candidate for Alzheimer’s disease. The anti-Abeta therapy “specifically targets the most toxic forms of Abeta” according to Dr Andrea Pfeifer, CEO of AC Immune SA.

Vaccines 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Teva and Fosun Pharma partner on early-stage oncology drug

Pharma Times

The drug is being evaluated as both a monotherapy and in combination with Merck & Co’s Keytruda (pembrolizumab) for cancers such as melanoma, after demonstrating tumour regression, enhanced T-cell infiltration, and durable immune memory in preclinical studies. This field is required.

article thumbnail

RVAC and University of Pennsylvania to develop mRNA vaccines

Pharmaceutical Technology

The collaboration, under a sponsored research agreement, will focus on mRNA vaccines that can help in modulating the normal immune response of the body for the treatment of certain autoimmune diseases as well as allergic conditions. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

article thumbnail

Kite and Daiichi Sankyo update cell therapy licensing agreement

Pharmaceutical Technology

Directed against a cell membrane protein called CD19, Yescarta uses the immune system of the patient to destroy cancer. By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy. By Cytiva Thematic.

article thumbnail

Hospital Universitario and Josep Carreras develop cell therapy for leukaemia

Pharmaceutical Technology

CAR-T therapies are based on the patient’s immune cell modification and can express artificial chimeric receptors that can identify and remove tumour cells. By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy.

Hospitals 110
article thumbnail

Episode 646: Does vaccine-induced immune thrombotic thrombocytopenia have a “pre-VITT syndrome” ?

Pharmacy Joe

In this episode, I’ll discuss a possible syndrome that might herald vaccine-induced immune thrombotic thrombocytopenia. Episode 646: Does vaccine-induced immune thrombotic thrombocytopenia have a “pre-VITT syndrome” ? 4 of the patients experienced thrombosis and 7 did not. appeared first on Pharmacy Joe.